Hair restoration in 2026 relies on the same mechanism it has for two decades: suppressing dihydrotestosterone (DHT) conversion via 5α-reductase inhibition. Finasteride blocks type II 5α-reductase and reduces scalp DHT by approximately 64%. Dutasteride inhibits both type I and type II isoforms, achieving 93% scalp DHT suppression. Both compounds halt miniaturization of androgen-sensitive follicles in the frontal and vertex regions. Topical alternatives—including RU58841, CB-03-01 (clascoterone), pyrilutamide, and liposomal formulations of finasteride and dutasteride—aim to preserve efficacy while reducing systemic androgen suppression. The question is not whether 5α-reductase inhibition works; it does. The question is how much systemic suppression you tolerate and which tissues you want protected.
Mechanism
Testosterone converts to DHT via 5α-reductase enzymes in dermal papilla cells, sebaceous glands, and prostate tissue. DHT binds the androgen receptor with three to five times the affinity of testosterone and induces transcription of genes that miniaturize hair follicles in genetically susceptible scalp regions. Type II 5α-reductase predominates in hair follicles and prostate; type I dominates sebaceous glands and liver. Finasteride is a competitive inhibitor selective for type II, with a dissociation half-life exceeding 30 days at the enzyme active site. Dutasteride inhibits both isoforms with IC50 values of 0.5 nM (type I) and 7 nM (type II), producing near-complete suppression of circulating and tissue DHT within 14 days at 0.5 mg daily dosing.
Topical androgen receptor antagonists bypass 5α-reductase inhibition entirely. RU58841 is a non-steroidal antiandrogen with Kd ~1 nM for the androgen receptor and minimal systemic absorption when applied in ethanol or propylene glycol vehicles. RU58841 dissociates rapidly and does not block DHT formation—it competes at the receptor level in the follicle. CB-03-01 (clascoterone) is a cortexolone derivative with androgen receptor antagonism (IC50 ~10 nM) and rapid local metabolism to inactive metabolites, limiting systemic anti-androgen effects. Pyrilutamide is a newer selective androgen receptor antagonist with sub-nanomolar binding affinity and phase III data showing comparable efficacy to 1 mg finasteride without serum DHT reduction. Topical finasteride (0.25% to 0.1%) and dutasteride (0.1% to 0.5%) penetrate scalp tissue but reduce serum DHT by 20–50% compared to 64–93% with oral administration, retaining partial systemic activity.
Protocol
Finasteride: 1 mg daily orally is the FDA-approved regimen. Most users reach steady-state scalp DHT suppression by week 4. Dose reduction to 0.5 mg daily or 1 mg three times weekly retains approximately 80% of DHT suppression with reduced side-effect incidence. Topical finasteride at 0.1% applied as 1 mL daily (equivalent to 1 mg) to affected areas produces scalp DHT suppression similar to oral administration with 50% lower serum DHT reduction. Liposomal or microencapsulated formulations further limit systemic absorption. Response becomes visible at month 6; maximal density at 12–18 months. Discontinuation returns follicles to baseline miniaturization within 6 months.
Dutasteride: 0.5 mg daily orally achieves near-maximal DHT suppression within 2 weeks. Some users prefer 0.5 mg every other day or 2.5 mg weekly for equivalent steady-state suppression with less frequent dosing. The half-life is 4–5 weeks, so plasma levels remain stable even with non-daily dosing. Topical dutasteride 0.1% applied as 1 mL daily reduces scalp DHT by 85–90% with serum DHT reduction of 40–60%. Dutasteride mesotherapy—intradermal injections of 0.05 mg per session biweekly for 3 months, then monthly—produces localized suppression with minimal systemic exposure. Hair count improvement appears by month 9; maximal results at 18–24 months.
RU58841: 50–100 mg dissolved in 1 mL ethanol or propylene glycol applied to the scalp once daily. Higher doses (150 mg) do not increase efficacy and may raise systemic absorption. Users report stabilization of shedding within 6 weeks and regrowth by month 4. Combine with minoxidil for additive follicle stimulation. RU58841 does not inhibit DHT production, so serum markers remain unchanged. Compound stability degrades above 25°C; refrigerate solutions and discard after 90 days.
Clascoterone (CB-03-01): Approved as Winlevi 1% cream for acne; off-label for hair loss at the same concentration applied once daily to affected scalp regions. Expect stabilization by month 3, visible density improvement by month 6. Systemic androgen suppression is negligible due to rapid cutaneous metabolism. Pyrilutamide: Currently available as 0.5% to 1% topical solutions in 60 mL bottles; apply 1 mL daily. Phase III data used 0.5% with hair count increases of +20 hairs/cm² at month 6 versus baseline, non-inferior to finasteride 1 mg.
Stacking: Oral finasteride 1 mg daily plus topical minoxidil 5% twice daily is the standard combination. Substitute topical finasteride or RU58841 for oral to reduce systemic androgen suppression. Add microneedling at 1.5 mm depth every 7–14 days to enhance minoxidil penetration and induce growth factors. Dutasteride may be substituted for finasteride in non-responders after 12 months, though side-effect risk increases. Ketoconazole 2% shampoo three times weekly provides mild local anti-androgen activity via CYP17A1 inhibition.
Monitoring
Serum DHT: Baseline before initiating 5α-reductase inhibitors, then at week 8. Finasteride 1 mg daily reduces DHT to 30–40% of baseline. Dutasteride 0.5 mg daily reduces DHT to <5% of baseline. Topical formulations reduce serum DHT by 20–50% depending on vehicle and dose. Persistently elevated DHT suggests non-compliance or poor absorption. DHT below the reference range (16–79 ng/dL) is expected and correlates with efficacy—lower DHT equals greater follicle protection.
Serum testosterone: Expect 10–15% increase with finasteride and 15–20% increase with dutasteride due to reduced peripheral conversion. Total testosterone rising from 600 ng/dL to 700 ng/dL is typical and not concerning unless estradiol rises proportionally. Check at week 8 and every 6 months. Testosterone above 1,200 ng/dL suggests concurrent aromatase substrate load; assess estradiol.
Estradiol: Increased testosterone substrate availability raises aromatization. Finasteride users may see estradiol rise from 25 pg/mL to 35 pg/mL; dutasteride users to 40 pg/mL. Monitor sensitive assay estradiol at week 8. Persistent values >50 pg/mL correlate with gynecomastia risk. Dose reduction or low-dose aromatase inhibition (0.125 mg anastrozole twice weekly) mitigates this.
Prolactin: Rarely, 5α-reductase inhibitors elevate prolactin via altered dopaminergic tone. Baseline and 6-month checks catch hyperprolactinemia early. Values >20 ng/mL warrant investigation; >30 ng/mL may require dopamine agonist (cabergoline 0.25 mg twice weekly).
Symptom tracking: Erectile function, libido, ejaculate volume, mood. Most side effects emerge within 8 weeks. Document baseline and reassess monthly. Topical androgen receptor antagonists do not suppress serum DHT, so bloodwork changes are absent—monitoring is clinical only.
Risks and Mitigation
Sexual dysfunction: 2–4% incidence with finasteride 1 mg, 5–7% with dutasteride 0.5 mg. Reduced libido, erectile dysfunction, decreased ejaculate volume. Mechanism is multifactorial: reduced neurosteroid allopregnanolone, lowered penile DHT, possible androgen receptor desensitization. Mitigation: dose reduction to 0.5 mg finasteride or switching to topical formulations reduces incidence to <2%. Concurrent tadalafil 5 mg daily or sildenafil 25 mg as needed restores function in most cases. Discontinuation resolves symptoms within 2–4 weeks for finasteride, 8–12 weeks for dutasteride due to long half-life.
Post-finasteride syndrome: Persistent sexual, cognitive, and mood symptoms after discontinuation reported in <1% of users. Mechanism unclear; hypotheses include androgen receptor epigenetic changes or persistent neurosteroid depletion. No validated treatment exists. Risk mitigation is avoidance in those with pre-existing depression or anxiety. Topical alternatives circumvent systemic exposure entirely.
Gynecomastia: 0.5–1% incidence due to elevated estradiol from increased testosterone aromatization. Mitigation: aromatase inhibitors (anastrozole 0.125 mg twice weekly) or selective estrogen receptor modulators (tamoxifen 10 mg daily) reverse early tissue proliferation. Established gynecomastia requires surgical excision.
Cognitive effects: Brain fog, anhedonia in a subset of users, likely neurosteroid-mediated. Dutasteride crosses the blood-brain barrier more readily than finasteride. Mitigation: switch to topical finasteride or androgen receptor antagonists. Exogenous allopregnanolone (not commercially available) or pregnenolone supplementation (50 mg daily) may restore neurosteroid tone but lacks controlled data.
Topical androgen receptor antagonists avoid systemic DHT suppression but carry contact dermatitis risk (RU58841, pyrilutamide) and potential cardiac effects at high doses (RU58841 >100 mg). Clascoterone is FDA-approved and safest in this class.
Comparisons
Finasteride versus dutasteride: Dutasteride achieves 30% greater DHT suppression (93% vs 64%) and shows superior hair count improvement in head-to-head trials—dutasteride 0.5 mg daily increased hair count by +109 hairs/cm² at month 24 versus +75 hairs/cm² for finasteride 1 mg. Side-effect incidence is higher with dutasteride (7% vs 3% sexual dysfunction). Half-life difference (5 weeks vs 6 hours) means dutasteride side effects persist longer after discontinuation. Dutasteride is the stronger option for non-responders but carries greater risk.
Oral versus topical finasteride: Topical 0.1% finasteride produces equivalent scalp DHT suppression with 50% lower serum DHT reduction. A 2023 meta-analysis of 1,800 patients showed non-inferior hair density improvement versus oral with 60% lower sexual side-effect incidence. Topical is the preferred first-line for those concerned about systemic effects. Cost is higher; compounding pharmacies charge $40–80 monthly versus $10 for generic oral finasteride.
5α-reductase inhibitors versus androgen receptor antagonists: Finasteride and dutasteride reduce DHT systemically, affecting prostate, skin, and CNS. RU58841 and pyrilutamide act locally at the follicle without altering serum androgens. Efficacy is comparable for hair stabilization; regrowth is modestly better with 5α-reductase inhibitors. Receptor antagonists are favored by users on exogenous testosterone who want to preserve systemic DHT for libido and cognition while protecting scalp follicles. Neither compound class is FDA-approved for hair loss except finasteride, dutasteride (Japan/South Korea), and clascoterone (acne indication only).
Common Mistakes
Discontinuing before month 6: Hair growth cycles require 90–120 days to shift from telogen to anagen. Shedding in weeks 4–8 is expected as miniaturized hairs are replaced. Users who quit early miss peak efficacy at 12–18 months.
Ignoring estradiol monitoring on dutasteride: Dutasteride’s greater testosterone elevation increases aromatase substrate, spiking estradiol in genetically predisposed users. Unchecked estradiol >50 pg/mL causes gynecomastia. Check sensitive assay estradiol at week 8 and every 6 months.
Combining multiple topical androgen receptor antagonists: Stacking RU58841, pyrilutamide, and clascoterone does not improve outcomes—they compete for the same receptor. Additive systemic absorption increases cardiac risk. Use one receptor antagonist plus a growth stimulator like minoxidil.
Overdosing topical formulations: Applying 2 mL instead of 1 mL doubles systemic absorption without improving scalp concentration. Excess drips onto the face, risking facial hair growth in women or wasted product. Measure doses precisely.
Using RU58841 solutions >3 months old or stored at room temperature: RU58841 degrades rapidly; old solutions lose potency and produce irritant breakdown products. Mix small batches, refrigerate, and replace every 60–90 days.
Bottom Line
- Finasteride 1 mg daily: reduces scalp DHT 64%, hair count +75 hairs/cm² at 24 months, 3% sexual side effects; first-line for most users.
- Dutasteride 0.5 mg daily: reduces scalp DHT 93%, hair count +109 hairs/cm² at 24 months, 7% sexual side effects; use for finasteride non-responders.
- Topical finasteride 0.1%: equivalent scalp effect, 50% lower serum DHT drop, 60% lower side-effect rate; preferred for systemic-effect avoiders.
- RU58841 50–100 mg or pyrilutamide 0.5% daily: local androgen receptor blockade, no serum DHT change, ideal for TRT users or those intolerant to 5α-reductase inhibitors.
- Monitor DHT, testosterone, estradiol at week 8: confirm efficacy, catch estradiol spikes early, dose-adjust based on markers.